Prevalence and prognostic effect of high tumor mutation burden (TMB-H) across multiple less common solid cancers using a real-world dataset Published September 2019 Citation Backenroth D, Shao C, Li G, Huang L,Pruitt SK, Castellanos EH, Frampton GM, Carson KR, Snow T, Singal G, Fabrizio D, Alexander BM, Jin FJ, Zhou W. . ESMO Annual Congress. . https://www.sciencedirect.com/science/article/pii/S0923753419600062 Authors:Backenroth D, Shao C, Li G, Huang L,Pruitt SK, Castellanos EH, Frampton GM, Carson KR, Snow T, Singal G, Fabrizio D, Alexander BM, Jin FJ, Zhou W Sources:ESMO Annual Congress Share Posted inPublicationsDrug discoveryTumor agnostic More publicationsESMO AI & Digital OncologyNovember 2025A pan-tumor and pan-country approach to LLM-based extraction of systemic therapies from the electronic health recordViani N, Groizard L, Harrison K, et al. Publication summaryPublicationsMachine learningTumor agnosticData managementJCO Cancer Clinical InformaticsMarch 2026Impact of real-world response to first-line immunotherapy and chemotherapy on subsequent treatment outcomes in patients with advanced or metastatic non-small cell lung cancerMalhotra J, Viswanathan S, Mhatre S, et al. Publication summaryPublicationsTreatment patternsNon-small cell lung cancerASCO GUFebruary 2026Persistent gaps in BRCA mutation testing among mCRPC patients: Insights from US cancer practices (2018–2024)McKay R, Li W, Roose J, et al.Publication summaryPublicationsProstate cancer